EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Myeloid neoplasm inspired intensive therapy in VEXAS syndrome: A single‐centre experience

Maël Heiblig iD, Adriana Plesa, Juliet Tantot, Yvan Jamilloux, Hélène Labussière-Wallet, Pierre Sujobert iD

British Journal of Haematology · 2025

DOI: 10.1111/bjh.20067 ↗

Kurz gefasst

Fallbericht in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Maël Heiblig und 5 weiteren Autor:innen. Beteiligte Einrichtung: Service d'hématologie Clinique, Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is still no standard of care and unmet medical needs in refractory/advanced VEXAS (vacuoles in myeloid progenitors, E1 ubiquitin activating enzyme, X‐linked, autoinflammatory manifestations and somatic) syndrome with or without associated haematological neoplasm. We report the clinical outcome of four multirefractory/advanced VEXAS patients treated with acute myeloid leukaemia‐like therapeutic approaches. All patients responded to inflammatory/haematological VEXAS‐related features, which were associated with measurable residual disease response (partial or complete). Prospective studies evaluating new and effective therapeutic strategies in order to reduce clonal burden in VEXAS patients are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteHumansUbiquitin-Activating EnzymesMyelodysplastic SyndromesSkin Diseases, Genetic

Stichwörter der Autor:innen

VEXASacute leukaemiavenetoclax

Substanzen

UBA1 protein, humanUbiquitin-Activating Enzymes

Autor:innen und Institutionen

  • Service d'hématologie Clinique, Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France.
  • Centre Hospitalier Lyon Sud and Université Claude Bernard Lyon-1, Pierre-Bénite, France.
  • Team Lymphoma Immuno-Biology, Centre International de Recherche en Infectiologie (CIRI), UMR INSERM U1111, CNRS 5308, Université Claude Bernard Lyon I, ENS de Lyon, Lyon, France.
  • Service d'hématologie biologique, Hospices Civils de Lyon, Lyon, France.
  • Service d'anatomopathologie, Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France.
  • Service de Médecine Interne, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France.

ORCID-Profile: Maël Heiblig, Pierre Sujobert

Zitieren

APA

Heiblig, M., Plesa, A., Tantot, J., Jamilloux, Y., Labussière-Wallet, H., & Sujobert, P. (2025). Myeloid neoplasm inspired intensive therapy in VEXAS syndrome: A single‐centre experience. British Journal of Haematology. https://doi.org/10.1111/bjh.20067

Vancouver

Heiblig M, Plesa A, Tantot J, Jamilloux Y, Labussière-Wallet H, Sujobert P. Myeloid neoplasm inspired intensive therapy in VEXAS syndrome: A single‐centre experience. British Journal of Haematology. 2025. doi:10.1111/bjh.20067

BibTeX
@article{Heiblig2025,
  author = {Heiblig, Maël and Plesa, Adriana and Tantot, Juliet and Jamilloux, Yvan and Labussière-Wallet, Hélène and Sujobert, Pierre},
  title = {Myeloid neoplasm inspired intensive therapy in VEXAS syndrome: A single‐centre experience},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.20067}
}
Kostenlos starten →